利福昔明对慢性活动性肝炎和代偿期肝硬化肠源性内毒素血症及肝脏炎症的影响  

Effect of rifaximin on enterogenous endotoxemia and liver inflammation in patients with chronic active hepatitis or compensated cirrhosis

作　　者：何云 赵翠萍 李虹 李琤 赵清霞 樊满齐[3] 

机构地区：[1]河南省传染病医院艾滋病病区,郑州450015 [2]甘肃宁县和盛医院一病区,745201 [3]成都军区昆明总医院呼吸科,650032

出　　处：《传染病信息》2012年第4期220-222,共3页Infectious Disease Information

摘　　要：目的 研究利福昔明对慢性活动性肝炎和代偿期肝硬化患者肠源性内毒素血症及肝脏炎症的影响。方法 选取慢性活动性肝炎和代偿期肝硬化患者共105例,随机分为2组,对照组给予常规保肝治疗,试验组在常规保肝治疗基础上给予口服利福昔明,疗程14d。比较治疗前后2组患者血液内毒素、白细胞介素(interleukin,IL)-6和肿瘤坏死因子(tumor necrosis factor,TNF)-α、ALT、TBIL、ALB的变化。结果 试验组治疗后内毒素水平下降幅度明显大于对照组(P<0.05),在改善血清IL-6、TNF-α、ALT、TBIL、ALB方面也优于对照组(P均<0.05)。结论 利福昔明能够纠正慢性活动性肝炎和代偿期肝硬化患者肠源性内毒素血症,下调促炎因子TNF-α和IL-6水平,降低ALT及TBIL水平,继而达到缓解肝脏炎症的作用。Objective To investigate the effect of rifaximin on enterogenous endotoxemia and liver inflammation in patients with chronic active hepatitis or compensated cirrhosis. Methods Totally 105 patients with chronic active hepatitis or compensated cirrhosis were selected and randomized into 2 groups. The control group received regular liver-protecting treatment for 14 days, while the experimental group received oral rifaximin in addition to regular liver-protecting treatment. The changes of the levels of endotoxin, interleukin （IL）-6, tumor necrosis factor （TNF）-alpha, ALT, TBIL and ALB before and after treatment were compared be- tween the two groups. Results Endotoxin levels of the experimental group decreased more greatly after treatment than those of the control group P〈0.05）. The levels of IL-6, TNF-α, ALT, TBIL and ALB of the experimental group improved more significantly than those of the control group （P〈0.05）. Conclusions Rifaximin can improve enterogenous endotoxemia, down-regulate the levels of TNF-α and IL-6, and reduce the levels of ALT and TBIL in patients with chronic active hepatitis or compensated cirrhosis, thereby relieving liver inflammation.

关 键 词：肝炎 慢性 肝硬化 内毒素血症 抗菌药 

分 类 号：R575.2[医药卫生—消化系统] R631.1[医药卫生—内科学]